KRAS G12V in PDAC — second-most common driver. No approved drug 2026; pan-KRAS inhibitors...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12V-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | KRAS G12V |
| Disease | DIS-PDAC |
| ESCAT tier | IV |
| Evidence summary | KRAS G12V in PDAC — second-most common driver. No approved drug 2026; pan-KRAS inhibitors and TCR therapies in trial. |
Notes
ESCAT IV. Encoded under BIO-RAS-MUTATION (no variant-specific BIO for KRAS G12V yet). FLAG: dedicated BIO-KRAS-G12V would improve granularity.
Used By
No reverse references found in the YAML corpus.